Now that the treatment landscape has thoroughly transformed for post-chemotherapy metastatic castration-resistant prostate cancer, the fast-evolving space is starting to see shifts in standard care in earlier stages of the disease, beginning with the approval of Johnson & Johnson’s Zytiga for the pre-chemotherapy setting and rapidly progressing with a lineup of clinical trials set to report data in the coming year.
Localized prostate cancer is initially managed through surgical and/or chemical castration with hormonal (androgen deprivation) therapy. Should it advance beyond that, castration- or hormone-resistant prostate cancer has been treated with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?